As shown in the ToGA clinical trial, the addition of trastuzumab, a recombinant humanized monoclonal antibody against Her2, to chemotherapy led to improved survival in HER2-positive advanced GEJ adenocarcinoma [54]. Here, ERBB2 is linked to gastroesophageal junction adenocarcinoma.